✦ LIBER ✦

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

✍ Scribed by Neugut, Alfred I.; Hillyer, Grace Clarke; Kushi, Lawrence H.; Lamerato, Lois; Leoce, Nicole; Ambrosone, Christine B.; Bovbjerg, Dana H.; Mandelblatt, Jeanne S.; Hershman, Dawn L.

Book ID: 125380200
Publisher: Springer Japan
Year: 2014
Tongue: English
Weight: 224 KB
Volume: 21
Category: Article
ISSN: 1340-6868
DOI: 10.1007/s12282-014-0543-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Economic Evaluation of Adjuvant Trast

An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

✍ Wen Chen; Zefei Jiang; Zhimin Shao; Qiang Sun; Kunwei Shen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Management and Outcome of HER2-Positive

Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era

✍ Carlo Palmieri; Deep Shah; Jonathan Krell; Ondrej Gojis; Katy Hogben; Pippa Ridd 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 432 KB

Adjuvant trastuzumab with chemotherapy i

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

✍ Heather L. McArthur; Kathleen M. Mahoney; Patrick G. Morris; Sujata Patil; Linds 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views

## Abstract ## BACKGROUND: Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, the benefit for women with small, node‐negative HER2‐positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. Therefore, a

Prognostic value of phosphorylated HER2

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab

✍ Kurebayashi, Junichi; Kanomata, Naoki; Yamashita, Tetsumasa; Shimo, Toshiro; Miz 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 412 KB

Why Adjuvant Trastuzumab Led to Better O

Why Adjuvant Trastuzumab Led to Better Outcomes in Women with High-Risk HER-2-Positive Breast Cancer

✍ Kadri Altundag; Mauricio Z. Baptista 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJ

PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN

✍ TY Chao; SC Chen; KJ Chang; HK Chang; DR Chen; MF Hou; RK Hsieh; WT Huang; LM Ts 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB